For many technology and pharmaceutical firms

A. a large portion of their value to an acquirer might relate to in-process research and development (IPR&D).

B. in-process research and development (IPR&D) acquired in a business combination that meets the separability criterion as an asset is recognized and measured initially at fair value.

C. the firm that developed the in-process research and development (IPR&D) expensed the costs as they were incurred.

D. all of the above

E. none of the above